Portfolio rockets through £100,000

Today was the best day yet for OPTI:Optibiotix.

I kept expecting it to pull back, but apart from the odd blip it just headed higher and higher.

A 9p rise to add to yesterday's 3p rise has bolstered paper profits by just under £9,000 to £30,472, which is a 61% rise on my average purchase price.

I always hoped this would happen at some point, but after three years of waiting I was beginning to despair.

I think the excitement spilled out to SBTX:SkinBioTherapeutics, as that climbed 14.6% today and is now making £657 (62%) profit on my much smaller investment.

All this takes my weekly improvement in value to £9,224 by Tuesday, and the portfolio value soars to £106,542. Surely it can't bust through £110K this week?

Let's look at a chart!

Oh yes - that's more like it - one to pin up on the wall before it has a chance to change its mind.

Meanwhile, back on planet earth, my over-allocation request for IKA:Ilika open offer shares was granted, so I got 500 for £100. It reduces my weighted average from about 55p to 43p, but it's very much a punt as I'm not massively optimistic. Exciting IP though, especially the potential for solid state batteries in vehicles.

My holding is still making a 54% loss of £362, but it was a 65% loss before the new shares were added at a discount - so huzzah!

As I was writing the 2-year review of my trading account last week, I shook my head bitterly at how useless I had been, and how this account was meant to have been fun. I said I wasn't going to throw any more money at it, but I may have lied.

Barclaycard sent me a letter offering £2,000 transferred to my bank account for 0% interest until Feb 2020.

Free money for 18 months!

Both my mortgage and the loan I took out to kick-start my portfolio expire in 12 months, so that still gives me 6 months using savings from them for the repayments, which will easily pay it off.

This could be my chance to kick-start the trading account - but do it properly this time.

So, the £2,000 is sat in my account and I already have 2 limit orders set up for tomorrow.

Same rules as before - no more than £500 per transaction, but I get 4 transactions to kick off with.

My plan is to go for 2 higher-priced reputable companies and 2 more risky penny shares.

I've already identified the good companies because I already have shares in them.

IQE:IQE is still being hammered by the shorters, but at below £1 has to be a bargain, so my limit order is for 99p.

CAML:Central Asia Metals should be added in my SIPP and not a trading account, as it's too good for that, but it's at such depressed levels there must surely be a quick breakout coming soon. I added an order at 240p for those.

Now I need to find 2 incredibly volatile penny shares and watch them like a hawk. I must remember my biggest lesson from last time - buy them on the way back up, not on the way down, as it's very hard to forecast how low they will go.

Gosh - so much fun and excitement this week - hope there's no big announcements else I might explode...

Week 155 Review - Aftershocks from last week keep the momentum upwards

Last week was so good, week 155 was always going to struggle in comparison, and it would have gone down as a really good week under normal circumstances. The value increased by £2,679 resulting in a paper profit of £12,800 and a total portfolio value of £97,218. Tantalisingly close to the significant £100K milestone.

No horror stories this week, with the worst performer MTFB:Motif Bio dropping 6% and going 7% down overall. I'm really surprised, as the NDA has been submitted for Iclaprim following successful Phase III trials, and yet the price is lower than it was before the Phase III success was announced. That doesn't make any sense to me whatsoever. With a £3,300 investment this is one of my bigger holdings. I suspect it will be bought out long before any commercialisation, but would rather the share price was already at a premium before that happens.

My other significant loser this week was KIBO:Kibo Mining which fell 5% and is now 43% down on my average purchase price. The delay in signing a PPA is quite intolerable given the assurances about how close the deal was. Add to that the sell-off of KAT:Katoro Mining over a year ago and no sign of in-specie dividend and I'm pretty down on this company now. I won't be selling at a loss, but I'll be getting out as soon as is practical.

There were three 5% risers this week.

TND:Tandem Group tends to move quite a lot when it does move. There are so few shares in circulation that one buy or sell can shift it by 2 or 3%, and it generally goes up and down 5p at a time. My holding is still 35% down and it's constantly frustrating that this company can trade on a P/E ratio of 3.8. There's just no appetite for the shares. I'm still holding because it would only take one significant announcement to put this on the radar and a re-rate would be significant and fast. With hindsight it was a mistake to buy into such a small company with such illiquid shares, but I'm here now for better or for worse.

AMYT:Amryt Pharma is gradually dragging itself towards profitability and climbed 5% this week. It's only down by 3% now, so may go green again soon. I sold the majority of my holding last year for a modest £149 (3%) profit when I needed lots of cash to buy IQE:IQE during the shorter wars. That decision made me over £1,500 in about a week, and much of the proceeds from that sale went into increasing my OPTI:Optibiotix holding, so selling these was a great move. I kept £1,540 worth as I think this could be big, but I was overweight with my original holding given the risk.

OPTI:Optibiotix was Share of the Week last week, and the rise continued this week. It was only 3p (5%) but that constituted most the of portfolio rise this week. All this despite no news, so looking forward to the next announcement. Having said that, in the bad old days an announcement was always sold into so maybe we're better off without!

RED:RedT Energy announced a massive deal this week to provide 700MWh of storage for the German grid. This is exactly the type of deal required, and the share price reacted accordingly. There was a 24% improvement which means my holding is now just 32% under water. I only have £1,063 invested as I do have concerns that the margins on each machine are too small, but it would take over 9,000 machines to complete the 700MWh capacity. This is just for Germany - what happens when other countries come on board?

Share of the Week was almost the winner last week when it went up 18%. This week SBTX:SkinBioTherapeutics went up 39% and is now 48% up on my original investment and making £507 potential profit. I would have sold at this level a few weeks ago - given I had a limit order for 18.7p for a while, and it's now 21p. However, news from OPTI:Optibiotix on plans for the share divi are making me re-think my plans.

I've been counting on free shares in SBTX:SkinBioTherapeutics ever since the spin-off, and so haven't been buying any more than my original small stake. It's looking like the share handout may not happen. I can see the reasoning behind it. Dish out millions of free shares and you can guarantee many people would sell them immediately for the cash. I wouldn't, but many would. Alternatively, if the OPTI:Optibiotix holding could be placed with an institutional investor, then the cash could be dished out as a dividend and the shares would be safe as the institution would be under a lock-in clause.

The likely impact is lots of people receiving the dividend would use it to buy SBTX:SkinBioTherapeutics shares and there would actually be a benefit to the share price. I suspect I would buy the shares because I don't want my stake in the OPTI:Optibiotix spin-offs to be diluted. I would have to fight with everyone else for them and would get fewer than I might have under an in-specie divi, but the share price for my existing holding would be protected. My only regret is that I didn't load up at 10p! I won't make the same mistake when the other divisions are spun off.

I suspect it won't keep going up much longer, but it will make a very attractive spike.

The ISA and share portfolio looks like this

			Weekly Change
Cash	£111.02		+£0
Portfolio cost	£56,047.10		+£0
Portfolio sell value (bid price - commission)	£63,463.30	(13.2%)	+£1,972.98
Potential profits	£14,928.30		+£1,929.61
Yr 3 Dividends	£59.28		+£0
Yr 3 Profit from sales	£11,984.62		+£0
Yr 3 Average monthly cash profit	£1,019.83	(21.8%)	-£20.40
Total Dividends	£1,238.33		+£0
Total Profit from sales	£18,697.12		+£0
Average monthly cash profit	£553.24	(11.8%)	-£3.59
(Sold stocks profit + Dividends - Fees / Months)

Nearly all the rise was increased profits. Next week sees the end of Year 3 so it's looking like a 20% realised profit is guaranteed for the year unless something goes bust next week. Long term profit is well over the 10% target and that's 10% of a much more valuable portfolio.

Nice.

The SIPP looks like this after week 139

			Weekly Change
Cash	£20.03		+£0
Portfolio cost	£27,893.76		+£0
Portfolio sell value (bid price - commission)	£33,443.54	(19.9%)	+£706.89
Potential profits	£8,369.41		+£825.78
Yr 3 Dividends	£292.57		+£0
Yr 3 Profit from sales	£1,619.73		+£0
Yr 3 Average monthly cash profit	£226.41	(9.7%)	-£6.66
Total Dividends	£1,208.67		+£0
Total Profit from sales	£10,544.92		+£0
Average monthly cash profit	£359.21	(15.5%)	-£2.60
(Sold stocks profit + Dividends - Fees / Months)

Nice increase in profit from OPTI:Optibiotix and CAML:Central Asia Metals finally had a green week. Small losses elsewhere lopped off £120 but a £706 rise is still healthy.

Not as extreme as the other chart, but most of the time has been in the black.

I've been allocated my full 500 shares in the IKA:Ilika open offer, and those will be added to my account next week. The purchase will increase my holding by 30% and bring my average price a long way down from 55p given they were bought at 20p. It was a speculative punt as I don't have a huge amount of faith in the board. They are a typical research focused company with not much clue on commercialisation. My main hope is they will be bought out for their IP, which could be very valuable for electric cars. Even with this extra purchase for £100, my total investment has only cost £665 so I'm happy to be along for the ride.

Not sure what else is due to happen next week. My main hope is OPTI:Optibiotix and SBTX:SkinBioTherapeutics can consolidate for a while at their current price before the next leg up.

Week 154 Review - Best ever week!

The week just kept getting better, peaking on Thursday with my best ever day. I was convinced Friday would put a spoiler on it, but Friday delivered too.

The reason for all the celebration was my long-time Nemesis Share OPTI:Optibiotix suddenly broke out and climbed from a bid price of 74p to 92p. That's worth around £13,500.

There were a few poor performers elsewhere eating into that, so the final position was an increase in portfolio value of £13,318 which is more than double my previous best ever week. The portfolio shot into the black by £10,120 and just 2 weeks after breaking the magic £80K, it smashed through £90K and stands at £94,407. I do believe the extra-magic £100K is within grasp!

There was only one seriously poor performer. CAML:Central Asia Metals is having a really hard time lately, and dropped another 8% to 230.5p this week. I can't understand why. They make tons of cash and give a considerable chunk of it back to investors. I've only got £3,564 invested, having sold about £1,000 worth when they were 330p and went over 10% of my portfolio, yet I've had £853 dividends in less than three years. They have just bought a new mine which should enhance their profitability even more. The P/E ratio is 10 based on last years profits, but they will double with the new mine. I really wish I had spare cash to top up at these prices, as I firmly believe they will be back to 340p before too long.

All the other losses were relatively small, but there were a lot of them.

Good news that CEY:Centamin seems to be turning around now, with a 5% climb this week. They are only down by 5% from when I purchased them now, after an inexplicable dive from 160p to 120p due to short term grade reduction and lower gold output as a result. That low grade ore has been worked now, so production should get back to normal and there should be a rapid return to 160p, at which point I may sell up so I have cash for CAML:Central Asia Metals or VRS:Versarien if that drops back below 100p.

AMYT:Amryt Pharma reversed the recent decline and rose 8% and is only 8% down on purchase price. I'm looking forward to the next results as I think people will be surprised how much income is coming in from Lojuxta sales.

TLOU:Tlou Energy actually went down from 6p to 5.8p this week, but as I bought another 10,200 shares on open offer at 5.75p with no commission, the performance of my holding improved by 8%. I'm still confident that with the current reserves this company will fly even without winning the tender to build a power station. It's just a question of how long it will take. I wouldn't be surprised if they end up selling out to the Botswana government once the full reserves are confirmed. They need the power and we have a massive gas reserve.

SBTX:SkinBioTherapeutics has been very quietly climbing this week. I didn't even notice until today, when I realised it's 9% up and has climbed 18% this week. Not long until human trials, then things could get interesting.

Share of the Week without a shadow of doubt is OPTI:Optibiotix. In fact, within a week I've earned more potential profit from this than any other share. It went up 27% and my holding is now making £19,268 (40%) potential profit.This is nothing though - the fun is only just beginning. There's a hell of a long way to go yet. I think there will be gradual climb to 120p as new investors come on board, then a lull for a while until announcement of a retail contract for "Go Figure" or big Sweetbiotix deal. That could catapult it to 200p by the end of 2019. 200p would give me £99,941 potential profit and it's not just a dream - it's easily achievable. The long wait has certainly been worth it.

I was worried the weekly snapshot wouldn't get to celebrate a graph like this, but the re-trace never came. That's the steepest climb ever!

The ISA and share portfolios looks like this

			Weekly Change
Cash	£111.02		-£500.50
Portfolio cost	£56,047.10		+£586.50
Portfolio sell value (bid price - commission)	£61,490.32	(9.7%)	+£9,361.56
Potential profits	£12,998.69		+£9,203.16
Yr 3 Dividends	£59.28		+£0
Yr 3 Profit from sales	£11,984.62		+£0
Yr 3 Average monthly cash profit	£1,040.23	(22.3%)	-£21.23
Total Dividends	£1,238.33		+£0
Total Profit from sales	£18,697.12		+£0
Average monthly cash profit	£556.83	(11.9%)	-£3.64
(Sold stocks profit + Dividends - Fees / Months)

The cost went up due to the TLOU:Tlou Energy open offer, and that reduced cash, although I added £86 fr the upcoming IKA:Ilika open offer which is why cash on dropped by £500. Potential profits soared, and there were some slightly reduced losses to add to that. Average monthly performance dropped a bit more than usual in percentage terms due to the sudden increase in portfolio value.

Gap cleared and left way behind.

The SIPP looks like this after week 138

			Weekly Change
Cash	£20.03		+£0
Portfolio cost	£27,893.76		+£0
Portfolio sell value (bid price - commission)	£32,736.65	(17.4%)	+£3,957.17
Potential profits	£7,543.63		+£4,019.65
Yr 3 Dividends	£292.57		+£0
Yr 3 Profit from sales	£1,619.73		+£0
Yr 3 Average monthly cash profit	£233.07	(10%)	-£7.06
Total Dividends	£1,208.67		+£0
Total Profit from sales	£10,544.92		+£0
Average monthly cash profit	£361.81	(15.6%)	-£2.64
(Sold stocks profit + Dividends - Fees / Months)

Profits soared, but were dampened by CAML:Central Asia Metals dropping 8%. Performance still looking amazing. Still no sign of the MMX:Minds + Machines recovery I was hoping for - if that happens I'll be selling them and buying more CAML:Central Asia Metals.

I've been trapped in a value range for almost a year - it may have just broken out.

As the trading portfolio reaches its 2nd anniversary this week, I reluctantly have to fess up what a disaster it is

			Weekly Change
Cash	£0.03		+£0
Portfolio cost	£345.65		+£0
Portfolio sell value (bid price - commission)	£180.22	(-47.9%)	+£0
Potential profits	£0		+£0
Year 2 Dividends	£0		+£0
Year 2 Profit	-£218.50		+£0
Yr 2 Average monthly cash profit	-£18.21	(-63.2%)	+£0.36
Dividends	£1.15		+£0
Profit from sales	-£241.35		+£0
Average monthly cash profit	-£10.01	(-34.7%)	+£0.10
(Sold stocks profit + Dividends - Fees / Months)

LION:Lionsgold is the only holding and it's been suspended for months. I'm showing a loss because I decided to move my JLP:Jubilee Platinum and KIBO:Kibo Mining shares into my ISA and when I did that I treated it as a sale at a loss from this account - and buying cheap shares in the ISA.

The idea was that I would find volatile shares and trade them on a frequent basis, however every share I chose tanked straight after, and as I didn't follow the rules and take a small loss, I ended up stuck with them for ages.

This account has held 4 companies in 2 years - a trading account should have 4 companies in a month! I'm not prepared to waste any more money on it, so it's staying like this until LION:Lionsgold goes into profit. If that doesn't happen then I may just abandon the whole experiment.

Hahahahahahahaha - what a heap of rubbish!

That's it for another week - not just another week - the best of weeks. A new benchmark to judge other weeks by. How long till this record gets broken?

Optibiotix goes stratospheric

Today's the day I've been dreaming of for years - the day OPTI:Optibiotix broke its shackles and took off for outer space.

An 11p rise on top of the 5p we have already seen this week and the bid price has hit 90p, the price I initially bought in at with 3,390 shares.

They say you shouldn't average down, but after 3 years of averaging down I've managed to get to just under 66p and 74,697 shares.

The massive surge this week has taken my paper profits for OPTI:Optibiotix to £17,774 and despite a red day elsewhere, moved the overall portfolio value up to £93,310.

I was celebrating breaking the magic £80K on Friday, and less than a week later we've smashed through £90K.

That spike will warm my heart every time I look back at this.

There are times when I began to doubt. Many, many times when I scratched my head in disbelief and wondered if it was ever going to happen.

Well today it happened.

What will I be writing at the end of the week?

Can the price hold and the portfolio value stay above £90K?

Time to go to the pub and raise a toast to OPTI

Optibiotix goes bonkers and my portfolio soars into profit

OK - I know it's only Tuesday, but what a week!

OPTI:Optibiotix finally took off, and although it might all fall apart tomorrow, I wanted to jump up and down and whoop till I'm hoarse just for one day.

There was a good rise yesterday and then a 5p rise in the bid price today, and lots of other shares finished blue as the combined portfolios zoomed into profit and hit an all-time high of £87,591.

That's an improvement of £6,372 in 2 days.

It looks even better in pictorial format

Oh yes you beautiful thing!

That leaves OPTI:Optibiotix on a potential profit of £11,798 which is around 25% and suddenly the three years of frustration holding these at a loss has melted away.

It wasn't just OPTI:Optibiotix making my mood soar today, as SBTX:SkinBioTherapeutics had a great day and went back into profit, as did PAF:Pan African Resources.

Normally I strictly wait until weekend to even entertain updating the chart, especially as many mid-week rises have come crashing down before I take my formal snapshot on Friday. At least if that happens I'll be able to look back at this chart and remind myself of just how good today feels.

Week 153 Review - Portfolio reaches new high despite N4 Pharma crash

A pretty good week, with the portfolio hitting a record high value, but offset by the biggest crash of any share I have ever owned. Fortunately OPTI:Optibiotix saved the day and enabled the new high. The gap between cost and value narrowed by £1,172 leaving the deficit at £3,198. The portfolio value surged past the magic £80K and ended the week at £81,133.

The catastrophic collapse was N4P:N4 Pharma which plummeted 61% from a small 2% profit to a thumping great 59% loss. This followed news that early trials with their Viagra replacement Sildenafil has fallen somewhat short of expectations. The RNS stated:

"it is clear from the preliminary PK data that the current formulation has not met the key target endpoints of the trial. To that end, the product formulation will need to be reviewed to assess what changes would be required to make the reformulated drug viable in the context of the Company's patent position."

We now have to wait until late August for the data, then work out what to do before paying for another trial.

This was meant to be the quick-start easy money drug to fund everything else, but now it's hit a brick wall there's no surprise to see the share price plummet.

I didn't sell as their Nuvec drug delivery system could be worth way more than the other drugs added together, but they have moved from a quick profit share to yet another long burner that will damage my paper performance for years.

SBTX:SkinBioTherapeutics is really punishing me for trying to get that extra 0.1p when it was flying high at 18p. Why didn't I just sell the things?! It dropped another 7% this week to 13p, possibly due to people selling so they can ride the OPTI:Optibiotix wave. I knew the shares would be traded. I knew it would drop back to these levels. Why was I so bloody greedy?

MTFB:Motif Bio also had a bad week, dropping 5% and helping dull any resolve to buy junior pharma companies in the future.

There was precious little good news this week, but TLOU:Tlou Energy climbed 5% and also let me have my full request for the open offer. That means I'll have another 10,200 shares on Monday increasing my holding by 30%, and they were purchased at a bargain 5.75p so will already be making profit as well as bringing down my weighted average.

OPTI:Optibiotix wins Share of the Week as they can currently do no wrong. A 3p rise this week was just 5% but it means I'm making paper profit of £5,822 and the party's only just started. There seems to be bigger volume, and the serial seller appears to have gone. There are so many big news stories that could break any day that things are really exciting. It's been an almost 3 year wait, but that has done me a favour, as rather than this being another £1,000 share, it's now a £49,000 share with the potential of allowing me to retire significantly earlier than I had thought.

The gap is narrowing, but the low points from 12 months ago are vanishing each week, so the trend line is flattening and could even take a dip. The 6-month trend line would be more spectacular.

Here's the performance of the ISA and share accounts

			Weekly Change
Cash	£611.52		+£0
Portfolio cost	£55,460.60		+£0
Portfolio sell value (bid price - commission)	£51,542.26	(-7.1%)	+£1,279.98
Potential profits	£3,795.53		+£1,345.94
Yr 3 Dividends	£59.28		+£0
Yr 3 Profit from sales	£11,984.62		+£0
Yr 3 Average monthly cash profit	£1,061.46	(23%)	-£22.11
Total Dividends	£1,238.33		+£0
Total Profit from sales	£18,697.12		+£0
Average monthly cash profit	£560.47	(12.1%)	-£3.69
(Sold stocks profit + Dividends - Fees / Months)

The rise in paper profit was all thanks to OPTI:Optibiotix, with losses elsewhere taking a small amount of that away in terms of portfolio value. I think this could be regarded as a nice, steady week.

Still quite a long way to go and the trend line is pointing in the wrong direction, but the main green line is heading up.

The SIPP looks like this after week 137

			Weekly Change
Cash	£20.03		+£0
Portfolio cost	£27,893.76		+£0
Portfolio sell value (bid price - commission)	£28,779.48	(3.2%)	-£107.25
Potential profits	£5,523.98		+£602.96
Yr 3 Dividends	£292.57		+£0
Yr 3 Profit from sales	£1,619.73		+£0
Yr 3 Average monthly cash profit	£240.13	(10.3%)	-£7.51
Total Dividends	£1,208.67		+£0
Total Profit from sales	£10,544.92		+£0
Average monthly cash profit	£364.45	(15.7%)	-£2.68
(Sold stocks profit + Dividends - Fees / Months)

The potential profits managed a reasonable increase but were held back by CAML:Central Asia Metals falling yet again. Why have I got no spare cash to top up on these - it's an amazing company and gob-smackingly cheap at this price. The collapse of N4P:N4 Pharma wiped out all the profits and dragged the portfolio down by £107. Thank goodness for OPTI:Optibiotix else it would have been so much worse.

A reasonably flat week despite all the drama.

Unfortunately next week sees the 2nd anniversary of me opening my trading account, so I'll have to report on it. No sign of LION:Lionsgold returning from suspension, so the curse of the trading account will continue for some time yet.

As well as the TLOU:Tlou Energy open offer, there is now an open offer for IKA:Ilika. I've only been allocated 64 shares which will cost me £12.80. That's a bit of a waste of time so I may apply for 500 and increase my holding by a third like I did with TLOU:Tlou Energy. Although this is still very much a research company, they have some strong IP and it's a market that could be massive, so I'm happy to punt another £100, but it's a bit of a gamble.

VRS:Versarien is still riding high so my cunning plan to get back in cheaper isn't working at the moment. Probably a good job, as I need to sell the likes of MMX:Minds + Machines to pay for them, and that's going nowhere fast.

Next week should see TLOU:Tlou Energy stage a bit of a recovery now the open offer is out of the way and the cash is in the bank. Most of my attention will be on OPTI:Optibiotix though, as there were no deals announced this week and it's rare two weeks go by without a new one.

Week 152 Review - Optibiotix soars, but will it last this time?

An absolutely brilliant week, with OPTI:Optibiotix awakening and climbing 7p. That's worth £5,250 on its own, but the portfolio did even better and climbed by £5,454 to reduce the deficit to £4,370 and increase the combined value to a record £79,960. So close to that magic £80K.

Only one share did really badly, with RED:RedT Energy dropping yet again and losing 6%. This desperately needs some news on sales as it has dropped 54% and is looking grim. I still believe they have a great product, especially in the Gen3 machines, but it needs a massive order for grid storage else the share price will go nowhere.

N4P:N4 Pharma went from loss into profit climbing 4%. It's only up by £27, but it's nice to see a bit of green.

TND:Tandem Group dropped way too much after last week's trading update, but happy to say it clawed back 5% this week but has a long way to go before going into profit.

KIBO:Kibo Mining is recovering some of the recent losses caused by impatience and irritation over the delayed Power Purchase Agreement and lack of transparency over why the delays are occurring. Trust in the board is waning badly and they need to do something to restore faith of shareholders. Despite the promise of the projects being worked on, I'm regarding the recent behaviour as a big red flag. I won't be investing for the long term, but bailing out as soon as my losses are recovered, unless they do something to make be believe they have shareholders interests at heart. It's upsetting that both KIBO:Kibo Mining and JLP:Jubilee Metals have lost my confidence due to the same behaviour, as they had so much promise.

Share of the Week is OPTI:Optibiotix by absolutely miles, with an 11% increase taking them 7% up and with paper profit of £3,582 making them the new Star Share. However, I'm genuinely expecting that profit to increase 100 times over the next 5 years. The rise on Friday followed last week's news that a major seller had finished their selling, and news mid-week of a new major investor crossing the 3% threshold, no doubt after holding the price back filling his huge deal. There are still traders at work, but the pressure holding the price back may have been released. It could be wishful thinking, but we'll find out next week.

The deficit more than halved this week. Brilliant!

Here's the performance of the ISA and share accounts

			Weekly Change
Cash	£611.52		+£11.38
Portfolio cost	£55,460.60		+£0
Portfolio sell value (bid price - commission)	£50,262.28	(-9.4%)	+£3,757.87
Potential profits	£2,449.59		+£2,311.30
Yr 3 Dividends	£59.28		+£15.13
Yr 3 Profit from sales	£11,984.62		+£0
Yr 3 Average monthly cash profit	£1,083.57	(23.4%)	-£22.01
Total Dividends	£1,238.33		+£15.13
Total Profit from sales	£18,697.12		+£0
Average monthly cash profit	£564.16	(12.2%)	-£3.41
(Sold stocks profit + Dividends - Fees / Months)

Increase in profit was all OPTI:Optibiotix, as was most of the reduced loss, but TND:Tandem Group and KIBO:Kibo Mining also contributed to the reduced losses. TND:Tandem Group also paid out a £15.13 dividend, but £3.75 of that went on ISA fees. Average monthly performance is still amazing.

Not quite halved the deficit as there are still some very big losses to recover.

The SIPP looks like this after week 136

			Weekly Change
Cash	£20.03		-£10.25
Portfolio cost	£27,893.76		+£0
Portfolio sell value (bid price - commission)	£28,886.73	(3.6%)	+£1,697.03
Potential profits	£2,921.02		+£1,298.57
Yr 3 Dividends	£292.57		+£0
Yr 3 Profit from sales	£1,619.73		+£0
Yr 3 Average monthly cash profit	£247.64	(10.7%)	-£9.42
Total Dividends	£1,208.67		+£0
Total Profit from sales	£10,544.92		+£0
Average monthly cash profit	£367.13	(15.8%)	-£3.05
(Sold stocks profit + Dividends - Fees / Months)

Same story as the other account, with OPTI:Optibiotix causing most of the increase in potential profit and reduced loss. CAML:Central Asia Metals is still holding back the rise though.

Back into positive territory - yippee!

Still waiting to see if I get my increased allocation of cheap TLOU:Tlou Energy shares. A positive video on Proactive Investors during the week has helped reassure me that this company has a lot of potential and is doing all the right things. I like it when investors are given the chance to participate in a fund raising this way, even if it's depressing the share price at the moment. I think it's in a better place than when the shares were 16p, so could treble in value quite quickly.

Words can't express how excited I am about OPTI:Optibiotix at the moment. All the head scratching at why the price was so depressed, the worry that I'd made a huge mistake selling all my VRS:Versarien holding to buy at 66p. It could be yet another false dawn, but the optimism at the end of the week feels somehow different, as if a dam has burst. The next few weeks could be truly spectacular. I certainly hope so!